Grant: Operating Grant - Secondary Analysis of Databases
Université Laval
$97,076.00
Dynamic biomarker model in Alzheimer's disease: trajectory analysis and modulating factors
EF 2011-12
Résumé
According to estimates, there were half a million people in Canada alone with dementia due to Alzheimer's disease (AD) in 2008, and an alarming four times that number of people at risk of progression to AD. This prevalence is expected to double in the next 30 years. In order to be maximally effective, therapies must be provided as early as possible in the disease time course, which necessitates accurate diagnostic information.
Biomarkers, both chemical and imaging, can fulfil the role of indicators of specific changes that characterize the progression of AD in vivo. Yet, their time ordering is not completely understood, nor is the impact of certain risk factors, e.g. APOE genotype and cerebro-vascular burden.
The objective of this proposal is to fulfill the need for accurate diagnostic and prediction of future disease course, by producing a comprehensive, dynamic AD biomarker model allowing the determination of AD trajectory and the assessment of risk factors impact.
Programme
Operating Grant - Secondary Analysis of Databases
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
231373
Name
Duchesne Simon
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Secondary Analysis of Databases
Projecttitle
Dynamic biomarker model in Alzheimer's disease: trajectory analysis and modulating factors
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$97,076
Cihrequipment2
$0
Programname2
Operating Grant - Secondary Analysis of Databases
Keyworddelim
Alzheimer'S Disease; Apolipoprotein E; Biomarkers; Cerebro-Spinal Fluid Amyloid Beta; Cerebro-Spinal Fluid Tau; Cerebro-Vascular Pathology; Cognition; Fdg Pet; Mri Volumetry; Statistical Analysis
Abstract
According to estimates, there were half a million people in Canada alone with dementia due to Alzheimer's disease (AD) in 2008, and an alarming four times that number of people at risk of progression to AD. This prevalence is expected to double in the next 30 years. In order to be maximally effective, therapies must be provided as early as possible in the disease time course, which necessitates accurate diagnostic information.
Biomarkers, both chemical and imaging, can fulfil the role of indicators of specific changes that characterize the progression of AD in vivo. Yet, their time ordering is not completely understood, nor is the impact of certain risk factors, e.g. APOE genotype and cerebro-vascular burden.
The objective of this proposal is to fulfill the need for accurate diagnostic and prediction of future disease course, by producing a comprehensive, dynamic AD biomarker model allowing the determination of AD trajectory and the assessment of risk factors impact.
Competitiondate
201104
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Duchesne, Simon
Approvedterm
2 ans 0 mois
Cihrcontribution2
Institute of Aging~ $97,076~ $0~